Literature DB >> 11114384

Crystal structure and ligand binding properties of the D1D2 region of the inhibitory receptor LIR-1 (ILT2).

T L Chapman1, A P Heikema, A P West, P J Bjorkman.   

Abstract

LIR-1 is an inhibitory receptor that recognizes class I MHC molecules and the human cytomegalovirus class I homolog UL18. Here, we report the 2.1 A resolution crystal structure of the ligand binding portion of LIR-1 (domains 1 and 2 [D1D2]) and localize the binding region for UL18. LIR-1 D1D2 is composed of two immunoglobulin-like domains arranged at an acute angle to form a bent structure resembling the structures of natural killer inhibitory receptors (KIRs). The LIR-1 binding site comprises a portion of D1 distant from the interdomain hinge region that constitutes the KIR binding site, consistent with differences in LIR-1 and KIR recognition properties and functions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114384     DOI: 10.1016/s1074-7613(00)00071-6

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  37 in total

Review 1.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

2.  Origin and evolution of the chicken leukocyte receptor complex.

Authors:  Nikolas Nikolaidis; Izabela Makalowska; Dimitra Chalkia; Wojciech Makalowski; Jan Klein; Masatoshi Nei
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

Review 3.  Structural basis for recognition of MHC and MHC-like ligands by natural killer cell receptors.

Authors:  Lu Deng; Roy A Mariuzza
Journal:  Semin Immunol       Date:  2006-06       Impact factor: 11.130

4.  Structure of UL18, a peptide-binding viral MHC mimic, bound to a host inhibitory receptor.

Authors:  Zhiru Yang; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-15       Impact factor: 11.205

5.  Crystal structures of the two membrane-proximal Ig-like domains (D3D4) of LILRB1/B2: alternative models for their involvement in peptide-HLA binding.

Authors:  Gol Nam; Yi Shi; Myongchol Ryu; Qihui Wang; Hao Song; Jun Liu; Jinghua Yan; Jianxun Qi; George F Gao
Journal:  Protein Cell       Date:  2013-08-17       Impact factor: 14.870

6.  Structure and flexibility of the extracellular region of the PirB receptor.

Authors:  Hedwich C Vlieg; Eric G Huizinga; Bert J C Janssen
Journal:  J Biol Chem       Date:  2019-01-23       Impact factor: 5.157

7.  A potential role for shed soluble major histocompatibility class I molecules as modulators of neurite outgrowth.

Authors:  Lorraine R Washburn; Dan Zekzer; Shoshana Eitan; Yuxin Lu; Hoa Dang; Blake Middleton; Christopher J Evans; Jide Tian; Daniel L Kaufman
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

8.  Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G.

Authors:  Mitsunori Shiroishi; Kouhei Tsumoto; Kimie Amano; Yasuo Shirakihara; Marco Colonna; Veronique M Braud; David S J Allan; Azure Makadzange; Sarah Rowland-Jones; Benjamin Willcox; E Yvonne Jones; P Anton van der Merwe; Izumi Kumagai; Katsumi Maenaka
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-09       Impact factor: 11.205

9.  Structural basis of collagen recognition by human osteoclast-associated receptor and design of osteoclastogenesis inhibitors.

Authors:  Joel Haywood; Jianxun Qi; Chun-Chi Chen; Guangwen Lu; Yingxia Liu; Jinghua Yan; Yi Shi; George F Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-07       Impact factor: 11.205

10.  KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C.

Authors:  Thorsten Graef; Achim K Moesta; Paul J Norman; Laurent Abi-Rached; Luca Vago; Anastazia M Older Aguilar; Michael Gleimer; John A Hammond; Lisbeth A Guethlein; David A Bushnell; Philip J Robinson; Peter Parham
Journal:  J Exp Med       Date:  2009-10-26       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.